Want to see PPCB full AI Analyst Report?
PPCB Stock Chart & Stats
$0.22
$0.00(0.00%)
At close: 4:00 PM EST
$0.22
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.95 - $268.03
Previous CloseN/A
Volume127.03K
Average Volume (3M)400.33K
Market Cap
$4.03M
Enterprise Value$2.63M
Total Cash (Recent Filing)$443.70K
Total Debt (Recent Filing)$1.57M
Price to Earnings (P/E)―
Beta-0.88
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,503,116
10 Day Avg. Volume553,394
30 Day Avg. Volume400,327
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.18
Price to Sales (P/S)0.00
P/FCF Ratio-40.64
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet CushionReported debt is minimal versus equity, which reduces near-term solvency risk and interest burden. For a pre-commercial biotech, low leverage provides structural flexibility to raise R&D funding on more favorable terms and reduces immediate bankruptcy risk over the next 2–6 months.
Board Experience In Finance And Capital RaisesAdding a director experienced in taxation, finance operations and capital raising strengthens governance and execution on financings. This materially improves the company's structural ability to secure funding and manage financial strategy during development stages.
Focused Oncology R&D StrategyA focused R&D model targeting metastatic cancer addresses a durable, high-unmet-need market where successful assets can command sustained demand. Proprietary therapeutics strategy aligns with industry economics that favor durable IP-driven returns if clinical milestones are met.
Bears Say
Minimal Commercial RevenuePractically no product revenue demonstrates a fully pre-commercial profile, meaning the business lacks internal cash generation from sales. Over months this keeps the company dependent on external financing and makes operational continuity contingent on successful capital raises.
Large Recurring LossesSustained, material net losses erode shareholder equity and increase dilution risk when funding is required. Persistent negative profitability also signals that milestones or cost reductions are needed to stabilize finances, posing structural risk to long‑term viability absent new funding.
Negative Operating Cash Flow / Cash BurnConsistent negative operating and free cash flow indicate ongoing cash burn and reliance on external capital. This creates structural financing risk: future dilution, shifted timelines, or program cuts if capital markets tighten or if the company cannot execute planned raises.
Propanc Biopharma News
PPCB FAQ
What was Propanc Biopharma’s price range in the past 12 months?
Propanc Biopharma lowest stock price was $0.95 and its highest was $268.03 in the past 12 months.
What is Propanc Biopharma’s market cap?
Propanc Biopharma’s market cap is $4.03M.
When is Propanc Biopharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Propanc Biopharma’s earnings last quarter?
Currently, no data Available
Is Propanc Biopharma overvalued?
According to Wall Street analysts Propanc Biopharma’s price is currently Overvalued.
Does Propanc Biopharma pay dividends?
Propanc Biopharma does not currently pay dividends.
What is Propanc Biopharma’s EPS estimate?
Propanc Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Propanc Biopharma have?
Propanc Biopharma has 3,503,116 shares outstanding.
What happened to Propanc Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Propanc Biopharma?
Currently, no hedge funds are holding shares in PPCB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Propanc Biopharma
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
3.67% Other Institutional Investors
96.33% Public Companies and
Individual Investors